1 completed, 1 terminated, 1 withdrawn. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow Bionomics Limited: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer. BNC101 Solution for Infusion, BNC101 in combination with FOLFIRI - Colorectal Cancer | Phase 1 | Terminated | Bionomics Limited | 22 | 2016-03-01 | 2019-01-16 |
| BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients Carboplatin, Gemcitabine, BNC105P - Ovarian Cancer | Phase 1 / Phase 2 | Withdrawn | Hoosier Cancer Research Network | 2012-10-01 | 2015-12-23 | |
| BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Everolimus, BNC105P - Renal Cell Carcinoma | Phase 1 / Phase 2 | Completed | Hoosier Cancer Research Network | 154 | 2010-01-01 | 2022-07-11 |
Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Kidney Neoplasms (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1)
BNC 105P (2) · Carboplatin (1) · Everolimus (1) · Gemcitabine (1) · IFL protocol (1)
Australia (3) · United States (2) · New Zealand (1) · Singapore (1)
Daniela Matei, M.D. (1) · Danny Rischin, Professor (1) · Thomas Hutson, D.O. (1)